Bristol Myers turns focus to AI costs after broad rollout to workersnews2026-06-03T17:58:20+00:00June 3rd, 2026|Endpoints News|
Axsome pushes back generic entry for narcolepsy drug until 2040news2026-06-03T17:37:25+00:00June 3rd, 2026|Endpoints News|
FDA guides pharma on explaining unapproved drugs to payorsnews2026-06-03T16:55:05+00:00June 3rd, 2026|Endpoints News|
What it will take for more employer GLP-1 coveragenews2026-06-03T15:24:16+00:00June 3rd, 2026|Endpoints News|
Regeneron doubles down on CytomX after other pharmas walked awaynews2026-06-03T14:56:16+00:00June 3rd, 2026|Endpoints News|
Mineralys makes money moves before looming hypertension approvalnews2026-06-03T14:32:15+00:00June 3rd, 2026|Endpoints News|
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesnews2026-06-03T11:00:46+00:00June 3rd, 2026|Endpoints News|
Lilly gives hospitals deadline to comply with 340B claims data policynews2026-06-02T17:50:25+00:00June 2nd, 2026|Endpoints News|
FDA details flexibilities for new cell and gene therapies to leverage past datanews2026-06-02T17:40:48+00:00June 2nd, 2026|Endpoints News|
Anti-aging biotech NewLimit raises $435M at $3B+ valuationnews2026-06-02T17:34:39+00:00June 2nd, 2026|Endpoints News|
